Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
Pre-Market: $159.80 +0.11 (0.07%) 9:18 AM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
Pre-Market: $159.80 +0.11 (0.07%) 9:18 AM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Zacks News
Johnson & Johnson (JNJ) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 7.28% and 3.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Should Invesco S&P 500 Low Volatility ETF (SPLV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPLV
J&J (JNJ) to Begin Q2 Earnings Season for Drug, Biotech Sector
by Zacks Equity Research
Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex. In the MedTech segment, recovery in surgical procedures and new product launches are likely to have pushed sales growth.
3 Quarterly Reports Investors Can't Ignore This Week
by Derek Lewis
We've got a loaded slate, including quarterly results from Netflix, American Express, and Johnson & Johnson. But how do estimates stack up heading into their respective prints?
Tesla Reports Wednesday: Global Week Ahead
by John Blank
Tesla (TSLA) kicks off after the market closes on Wednesday. Big Tech stock market values exceed that of some nations' entire economies!
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $157.97, marking a -0.42% move from the previous day.
Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VYM
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Passive Income: 3 Dividend Kings Worth a Look
by Derek Lewis
Dividends soften the blow from drawdowns in other positions, provide more than one way to reap a return from an investment, and allow maximum returns through dividend reinvestment.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Can Eli Lilly's (LLY) Continue its Ride on Obesity Drug Wave?
by Zacks Equity Research
Lilly (LLY) continues to raise the bar on obesity drugs as latest data show that participants treated with these experimental drugs achieved mean weight reduction of up to 24%.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $163.35 in the latest trading session, marking a -1.31% move from the prior day.
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $163.63, moving -1.12% from the previous trading session.
Take the Zacks Approach to Beat the Market: Shopify, Oracle, Uber in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Johnson & Johnson (JNJ) Stock Moves -0.06%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $164.13 in the latest trading session, marking a -0.06% move from the prior day.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold
by Zacks Equity Research
Mersana's (MRSN) shares decline on partial clinical hold by the FDA on UP-NEXT and UPGRADE-A studies evaluating upifitamab rilsodotin to treat platinum-sensitive ovarian cancer.
AbbVie's (ABBV) Skyrizi Meets Ulcerative Colitis Study Goals
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remission in a late-stage study as a maintenance treatment for ulcerative colitis.
Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data
by Zacks Equity Research
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) CAR T cell therapy has achieved an overall response rate of 83% in patients with Waldenstrom macroglobulinemia.
The Zacks Analyst Blog Highlights Johnson & Johnson, Oracle, HSBC, NVIDIA and The Cigna Group
by Zacks Equity Research
Johnson & Johnson, Oracle, HSBC, NVIDIA and The Cigna Group are part of the Zacks top Analyst Blog.